Day: December 13, 2019

Skano Group AS muutis ärinime, uueks ärinimeks on alates 11.12.2019 Nordic Fibreboard AS. Otsus nime muutmise kohta võeti vastu aktsionäride koosolekul 14.10.2019 Torfinn LosvikJuhatuse esimeesPhone: + 372 56 99 09 88Email: torfinn.losvik@nordicfibreboard.com

Absence of neutropenia after six treatment cyclesImproved efficacy and tolerability even at quarter dose of docetaxelMONTREAL, Dec. 13, 2019 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to report on new data presented today at the San Antonio Breast Cancer Symposium (SABCS).Results from in vitro and in vivo experiments demonstrated that TH-1902 (docetaxel conjugated to Theratechnologies’ novel investigational peptide TH19P01), currently being developed for the treatment of triple-negative breast cancer (TNBC), improves efficacy and tolerability compared to docetaxel alone.Poster highlights(https://www.theratech.com/wp-content/uploads/2019/12/SABCS_2019.pdf)Data presented at the SABCS demonstrated:Stronger and sustained inhibition...

Absence de neutropénie après six cycles de traitementsEfficacité améliorée même à un quart de la dose de docétaxelMONTRÉAL, 13 déc. 2019 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), une société pharmaceutique au stade de la commercialisation, est heureuse de faire état de nouvelles données présentées aujourd’hui dans le cadre du San Antonio Breast Cancer Symposium (SABCS).Les résultats des expériences in vitro et in vivo démontrent que le TH-1902 (docétaxel conjugué au nouveau peptide expérimental de Theratechnologies TH19P01), présentement en développement pour le traitement du cancer du sein triple négatif (CSTN), permet d’améliorer l’efficacité et l’innocuité du docétaxel seul.Faits saillants de la présentation(https://www.theratech.com/wp-content/uploads/2019/12/SABCS_2019.pdf)Les données...

NEW YORK and TORONTO, Dec. 13, 2019 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), the leader in augmented reality (AR) for eCommerce and AR learning applications is pleased to announce Davidson’s Inc., one of the largest American firearms distributors, has now adopted NexTech’s AR for both its B2C and B2B business. This is the first sign-up of the previously announced new major expansion contract with Walther Arms to provide its dealers, numbering in the thousands, with the WebAR 3D experience.As an early adopter, Walther has had the opportunity to analyze the NexTech data and analytics dashboard and based on the extremely positive results, has agreed to cover the cost for their top 25 dealers to adopt AR and specifically the PPQ M2. Davidson’s Inc. facilitates every major American brand...

EDMONTON, Alberta, Dec. 13, 2019 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) announces a proposed shares-for-debt transaction in which the Company would issue 192,907 common shares, at a price of CAD $0.41 per share, to an arm’s length third party creditor of the Company in connection with the settlement of an aggregate of USD $60,000 of debt. The shares for debt transaction is subject to approval by the TSX Venture Exchange. All securities to be issued pursuant to this settlement will be subject to a 4-month hold period.About Radient:Radient Technologies is a commercial manufacturer of high quality cannabinoid based formulations, ingredients and products. Utilizing a proprietary continuous-flow extraction and processing platform that recovers up to 99% of cannabinoids...

CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) — Today, Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 2 PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear palsy (PSP). The primary endpoint, as measured by the PSP rating scale (PSPRS) at week 52, was not statistically significant. In addition, the study did not demonstrate efficacy on key clinical secondary endpoints. Based on these results, Biogen will discontinue development of gosuranemab for PSP and other primary tauopathies.“We are disappointed with the efficacy results of the Phase 2 PASSPORT study,” said Alfred Sandrock Jr., M.D., Ph.D., Executive Vice President, Research and Development and Chief Medical Officer at Biogen. “We remain unwavering in our commitment to advancing therapies that have the potential to address the significant...

VANCOUVER, British Columbia, Dec. 13, 2019 (GLOBE NEWSWIRE) — Ceylon Graphite Corp. (“Ceylon Graphite” or the “Company”) (TSX-V: CYL) (OTC: CYLYF) (FSE: CCY) today announced that its wholly owned  subsidiary Sarcon Development (Pvt) Ltd (“Sarcon”) has started commercial production at its K1 Graphite Mining Project at Karasnagla, Sri Lanka (the “K1 Project”).“We are finally in commercial production mode and look forward to selling our first container of Sri Lankan vein graphite- today we have brought 2 tons of raw graphite to the surface,” said Bharat Parashar, Chief Executive Officer. “These 3 years have been a learning process and  whilst this is just the first step to creating a globally recognized  graphite mining company, we are now much better prepared to develop our next sites and at a faster pace. I would also like to place...

In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-retinal fluid and/or sub-retinal fluid at week 16 and year one with Beovu1 In a key pre-specified secondary endpoint, over half of Beovu 6mg patients (56% in HAWK and 51% in HARRIER) were maintained on three-month dosing intervals immediately after the loading phase through year one1 Frequent injections are a common reason patients drop off treatment for wet AMD, a leading cause of blindness that affects more than 20M people worldwide2-4 Basel, December 13, 2019 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Beovu® (brolucizumab 6...

ORLANDO, Fla., Dec. 13, 2019 (GLOBE NEWSWIRE) — Nearly every person suffering from atopic dermatitis, more popularly known as “eczema,” knows just how difficult it can be to find effective remedies for his or her condition. Many prescription and over-the-counter treatments are not always consistent in providing relief, making new revolutionary improved topical medications a welcome addition to the narrow range of dermatological products dedicated to treating this difficult-to-cure ailment. Hoth Therapeutics, Inc. (NASDAQ:HOTH), is one such pharmaceutical company focused on providing eczema patients with a non corticosteriod therapeutic that actually helps treat eczema rather than just stop the itch.BioLexa – A Competitive Advantage Among Its Industry PeersDespite the relatively narrow regime of therapies for atopic dermatitis,...